|
|
|
|
|
|
|
|
|
|
|
|
|
13.01.26 - 12:00
|
SciNeuro and Novartis sign global licensing deal for Alzheimer′s antibody (PBR)
|
|
|
The agreement will leverage SciNeuro's proprietary blood-brain barrier shuttle technology, aiming to deliver potential differentiation from current amyloid beta agents in development or on the market. Both companies
The post SciNeuro and Novartis sign global licensing deal for Alzheimer's antibody appeared first on Pharmaceutical Business review....
|
|
|
13.01.26 - 10:18
|
Roche Neutral (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Roche nach einer Präsentation auf der JPMorgan-Healthcare-Konferenz auf "Neutral" mit einem Kursziel von 350 Franken belassen. Das starke Wachstum des zugelassenen Medikamenten-Portfolios ......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.01.26 - 06:12
|
China′s SciNeuro, Novartis sign US$1.7 billion licensing deal to develop Alzheimer′s drugs (SCMP)
|
|
|
A partnership between China's SciNeuro Pharmaceuticals and Swiss pharmaceutical giant Novartis on Monday has revived hopes for treating Alzheimer's disease.
The deal, worth nearly US$1.7 billion, grants Novartis exclusive worldwide rights to develop and commercialise SciNeuro's antibody candidates to develop drugs for the progressive brain disease.
SciNeuro's novel amyloid beta targeted antibody programme leverages proprietary blood-brain barrier shuttle technology to help more of the drug cross......
|
|
|
|
|
|
|
|
|
|
|
12.01.26 - 15:06
|
LabCentral Names Kamran Tavangar Head of Science Strategy (PR Newswire)
|
|
|
Affinivax Cofounder and Former Novartis Executive to Expand Scientific Programming and Collaboration CAMBRIDGE, Mass., Jan. 12, 2026 /PRNewswire/ -- LabCentral today announced the appointment of Kamran Tavangar as Head of Science Strategy. In this new executive role, Kamran will shape......
|
|
|
12.01.26 - 15:03
|
Corporate News: Sandoz Group AG (EQS)
|
|
|
Sandoz CEO, speaking at 44th Annual J.P. Morgan Healthcare Conference, will outline plans to capitalize on unprecedented 'golden decade' of affordable medicines opportunity...
|
|